SCHEMBL19628322

SCHEMBL19628322

CC1CC(C(=O)C2C(=O)CC(C)(C)OC2=O)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.35
SETD7 Q8WTS6 2/20 0.34
HSD17B10 Q99714 1/20 0.33
RECQL P46063 1/20 0.33
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31
MAPT P10636 1/20 0.31
PTPN2 P17706 1/20 0.31
PTPN1 P18031 1/20 0.31
PTPN6 P29350 1/20 0.31
GAA P10253 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM1 P11229 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31001845 0.87 GPR119 (0.37) GPR119SETD7HSD17B10RECQLHPGD
SCHEMBL16680966 0.87 GPR119 (0.37) GPR119SETD7HSD17B10RECQLHPGD
SCHEMBL31001854 0.87 GPR119 (0.37) GPR119SETD7HSD17B10RECQLHPGD
SCHEMBL16680969 0.87 GPR119 (0.37) GPR119SETD7HSD17B10RECQLHPGD
SCHEMBL19633443 0.81 GPR119 (0.35) GPR119SETD7HSD17B10RECQLHPGD
SCHEMBL17730433 0.73 ATM (0.34) HSD17B10RECQLHPGDDDB1CRBN
SCHEMBL23694162 0.71 HSD17B10 (0.44) GPR119SETD7HSD17B10RECQLHPGD
SCHEMBL15491795 0.71 HSD17B10 (0.44) GPR119SETD7HSD17B10RECQLHPGD
SCHEMBL6774754 0.71 HSD17B10 (0.44) GPR119SETD7HSD17B10RECQLHPGD
SCHEMBL23694159 0.71 HSD17B10 (0.44) GPR119SETD7HSD17B10RECQLHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334917-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-23 US disclosed
US-20170334917-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334917-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE HAMP, SERPINC1, PRSS8 GPR119 4770/4885SETD7 3129/4885HSD17B10 3305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.